Skip to content

Author

Abigail H. Evered

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages

The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is an established driver of inflammation in diseases such as diabetes, Alzheimer's disease, and gout. Previously, we screened 875 FDA-approved drugs for NLRP3 inhibitors and identified ponatinib as one of the five candidates that reduced NLRP3...

Abigail H. Evered, Daniel C. Shippy, Jaidynne N. Lash et al. · 0 citations
Open access Jul 2026

Equol inhibits NLRP3 inflammasome activation in macrophages 2257578

The intestinal microbiome produces a vast number of metabolites. Many of these metabolites have immunomodulatory properties including the ability to inhibit the NOD, LRR, and pyrin-domain containing 3 (NLRP3) inflammasome, an established driver of inflammation in many diseases including gout, psoriasis, and Alzhe...

Abigail H. Evered, Daniel C. Shippy, Tyler K. Ulland · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.